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Abstract
Background: The literature is inconclusive as to whether the percentage of the lepidic component of an invasive
adenocarcinoma (AC) of the lung influences prognosis. We studied a population-based series of selected, resected
invasive pulmonary ACs to determine if incremental increases in the lepidic component were an independent,
prognostic variable.
Methods: Patients undergoing resection for lung cancer reported to the Cancer Registry of Norway and diagnosed
in the period 1993-2002 with a bronchioloalveolar carcinoma (BAC) (old terminology) (adenocarcinoma in situ, AIS
in the new terminology) in the lung were selected. A pulmonary pathologist reviewed all sections and estimated
the percentage of the lepidic component. Follow-up of survival was to the end of 2013.
Results: One hundred thirty-one patients were identified, 102 had AC with lepidic growth. Of these, 44 had AC with
a component of lepidic growth less than 50 % and seven had AC with 95 % lepidic component or more. One of
the latter cases was considered to be AIS. In regression analyses, superior survival was associated with a greater
lepidic component (p = 0.041). Mucinous tumors had a worse prognosis than non-mucinous (p = 0.012) in regression
analyses, as did increasing age and stage. The five-year observed survival was 69.0 % for non-mucinous cases and
66.7 % for the group with a lepidic component of 80 % or greater.
Conclusion: The percentage of the lepidic component appears to be an independent, significant prognostic factor in
a selection of pulmonary AC.
Keywords: Adenocarcinoma in situ (AIS), Lepidic growth, Prognosis, Population-based survival, Lepidic predominant
adenocarcinoma (LPA) Bronchioloalveolar carcinoma (BAC)
Background
New concepts were introduced in the 2011 classification
of lung adenocarcinomas (ACs) by the International As-
sociation for the Study of Lung Cancer, American Thor-
acic Society, and European Respiratory Society [1]. One
was the lepidic-predominant adenocarcinoma (LPA) for
diagnoses based on resections. This property was first
noted by Noguchi in 1995 [2] and has later been found
to indicate a favorable prognosis [3] and with 5-year dis-
ease free survival of 94 % [4].
When LPA was introduced in the 2011 classification,
histologic subtyping to assess the different patterns semi-
quantitatively in 5 % increments and describing a single
predominant pattern for the diagnosis were suggested. The
recording of the percentage of a tumor component was
classified in the paper as ‘a weak recommendation’ with
‘low-quality evidence, ’ probably because of the lack of re-
search on this topic.
The association between the percentage of lepidic
component and prognosis is not well known. Recently
Kadota and colleagues reported that higher percentage
of lepidic pattern correlated with lower risk of recur-
rence [5]. Takahashi and colleagues studied AC patterns
(including LPA) quantitatively but the effect of the incre-
ments in the lepidic component was not specified other
than for the groups predominant and not-predominant
[3]. Also, quantification of the component has been used
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to estimate the non-lepidic tumor diameter, which
proved useful prognostically [6, 7].
The aim of the current paper is to investigate the ef-
fect of the percentage of the lepidic component as an in-
dependent prognostic factor in a population-based series
of pulmonary resections reported to the cancer registry
as ‘bronchioloalveolar carcinoma’ (‘BAC’). This entity is
now termed adenocarcinoma in situ (AIS), if there is no
invasion.
Methods
19,688 patients reported to the Norwegian Cancer Registry
were diagnosed with lung cancer in Norway in the period
1993-2002. Among these, 3,306 lung resections were per-
formed on 3,286 patients. A total of 5,113 cases was diag-
nosed as adenocarcinoma (26 %) in this period and of
these 1,396 were resected. A diagnosis of LPA or BAC (this
diagnosis made before the new nomenclature proposal in
2011 [1]) was reported to the Cancer Registry in 267 cases
(0.5 % of cases diagnosed as adenocarcinoma). 131 of these
267 cases were resected and thus further investigated.
Of these 131 cases initially reported as LPA or BAC, all
histological sections were reviewed by one pulmonary
histopathologist (PH), blinded from any clinical data. The
new international multidisciplinary classification of pul-
monary AC was used [1]. Only haematoxylin and eosin (H
& E) sections were available, unless special stains were
provided. All the sections, including normal lung, were
reviewed; the major type of AC present was noted, as well
as other subtypes. The percentage of the lepidic compo-
nent was estimated semi-quantitatively in five percentage
point increments on all sections from any case, rounded
up and the mean determined for the total number of
slides for the case. The cell type (mucinous and/or non-
mucinous) of the lepidic component was noted. Sex, age,
location of the tumor (left or right side), tumor size, as
measured macroscopically, and pTNM (7th ed. data) were
available for all cases but these details were not known by
the reviewing pathologist.
Cases with a primary lung cancer other than AC, AC
with no lepidic component or where it was impossible
to determine the histological subtype were excluded.
Cases with AIS were excluded from survival analyses.
AIS cases were classified with T-descriptor according to
tumor size and other features and not limited to Tis.
Univariate analyses were performed with the Chi-
square test. The Kruskal Wallis test was used to com-
pare non-parametric tumor sizes between the different
groups. Observed survival was estimated using the life
table method and calculated from the date of surgery to
death, emigration from the country or end of follow-up
(December 31 2013).
Multivariate Cox regression analysis was used to iden-
tify important survival factors. Included in the Cox
analysis were age (continuous), sex, side of resection
(right/left), surgical procedure and technique (sublobar
resection/lobectomy/bilobectomy and pneumonectomy),
tumor pStage (I-IV), tumor size (continuous)(whole tumor
as measured by the initial pathologist), proportion of the
lepidic component in percentage (continuous) and cell type
in the lepidic component (mucinous/non-mucinous/com-
bination). Pleural invasion is known to be an adverse prog-
nostic factor [8–11]. However, it was not analysed as an
independent variable since it would introduce an inter-
action with stage.
The software package R version 3.2.0 was used for
statistical analyses. (Foundation for Statistical Comput-
ing, Vienna, Austria; http://www.R-project.org).
Virtually all Norwegian cancers are reported to the
Cancer Registry [12]. Norwegian legislation does not re-
quire informed patient consent for studies based on data
from central registries. The study was approved by the
regional ethics committee.
Results
Of the 131 cases initially reported as ‘BAC’; twenty nine
were excluded (Fig. 1). The remaining 102 cases were
classified as adenocarcinomas with a lepidic component
(ALC) not BAC.
The mean age for patients with ALC was 65.2 years
(men 64.9, women 65.5). The number of sections per
case, including non-tumor, ranged from 2 to 35 (average,
5.3 sections/case).
The distribution of the lepidic component ranged from
5-100 % and the histogram is displayed in Fig. 2. Of the
ALCs, one was regarded adenocarcinoma in situ (AIS)
with a pure lepidic component, the tumor size was 1.8
centimeter in diameter and it was pStage IA. Another
six patients had lepidic components ranging from 96-
100 %. No minimal invasive adenocarcinoma (MIA) was
identified.
The remaining 96 cases had invasive AC with a vary-
ing lepidic component up to and including 95 %. In one
case, it was impossible to determine the percentage of
lepidic growth, in a predominantly papillary AC.
The characteristics (age, sex, side involved, pStage and
type of the lepidic component) for cases with ALC ac-
cording to the percentage of the lepidic component are
presented in Table 1. In 13 cases the cell type in the le-
pidic component had both mucinous and non-mucinous
cells lining the alveolar walls.
The mean tumor size in non-mucinous cases with ALC
(n = 71) was 3.1 cm, in mucinous cases (n = 17) 5.8 cm
and in mixed cases (mucinous & non-mucinous, n = 14)
3.9 cm. The sizes were significantly different between
these groups (p = 0.010).
The 1-, 2-, 5- and 10-year survivals, as well as the in-
fluence of the varying lepidic component percentages
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Fig. 2 Proportion of lepidic component in resected patients with lepidic predominant adenocarcinoma
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and type are shown in Table 2 and Fig. 3. The two
groups with highest percentage of lepidic component
had a moderately improved survival compared to the
two groups with the lowest percentage. In univariate
analyses the mucinous subtype appeared to have a worse
prognosis, although the confidence intervals had a small
overlap.
Multivariate analyses demonstrated that the independ-
ent variables important for survival were age, pStage, the
percentage and type of the lepidic component (Table 3).
No interactions were found, and proportional hazards
were not violated.
Discussion
This study demonstrates an independent, positive prog-
nostic association with incremental increases in the per-
centage of the lepidic component associated with
selected cases of invasive pulmonary AC. The five-year
observed survival rate was 56 % in the two groups classi-
fied with lepidic component percentage less than 80 %
and 67 % in the two groups with 80 % or more despite
the latter groups having a higher proportion of mucin-
ous cases.
Increasing proportions of the mucinous lepidic type
among the group with the highest percentage of lepidic
growth as well as not using cancer-specific death as end-
point for survival could explain why the 5-year survival
for these groups was not close to 100 %, as reported by
others [13]. Many cases had both a mucinous and non-
mucinous lepidic component, suggesting the neoplastic
process was differentiating along two cell pathways. Di-
vergent growth patterns are common in lung carcino-
genesis [14].
Five studies have previously quantitated the percentage
of the BAC component but not in the same way as this
investigation [3, 15–18]. Carretta et al. in patients with
Stage IA disease with > 50 % ‘BAC’ component had an
Table 1 Characteristics of adenocarcinoma with a lepidic
component by percentage of the lepidic component
Lepidic component
<50 % 50-75 % 80-95 % 96-100 % p-value
Total 44 (44) 26 (26) 24 (24) 7 (7)
Sex 0.49
Female 21 (39) 13 (24) 15 (28) 5 (9)
Male 23 (49) 13 (28) 9 (19) 2 (4)
Age (years) 0.43
<50 2 (33) 1 (17) 1 (17) 2 (33)
50-59 10 (44) 7 (30) 4 (17) 2 (9)
60-69 16 (47) 7 (21) 9 (27) 2 (6)
70+ 16 (42) 11 (29) 10 (26) 1 (3)
Side 0.11
Left 14 (36) 8 (21) 12 (31) 5 (13)
Right 30 (48) 18 (29) 12 (19) 2 (3)
pStage 0.71
I 29 (45) 14 (22) 16 (25) 6 (9)
II 11 (46) 7 (29) 5 (21) 1 (4)
III 4 (33) 5 (42) 3 (25) 0 (0)
Lepidic type 0.0024
Mucinous 5 (29) 2 (12) 5 (29) 5 (29)
Non-mucinous 35 (49) 20 (28) 14 (20) 2 (3)
Mucinous and
non-mucinous
4 (31) 4 (31) 5 (39) 0 (0)
Tumor size (centimeter) 0.64
<3 23 (52) 9 (21) 10 (23) 2 (5)
3-5 14 (33) 14 (33) 10 (24) 4 (10)
5+ 7 (47) 3 (20) 4 (27) 1 (7)
Table 2 Survival according to the lepidic component and type
N 1 yr. (95 % CI) 2 yr. (95 % CI) 5 yr. (95 % CI) 10 yr. (95 % CI)
Total 101 84.2 (77.3-91.6) 76.2 (68.3-85.0) 58.1 (49.2-68.6) 34.1 (25.9-44.8)
Lepidic component
<50 % 44 84.1 (73.9-95.6) 72.6 (60.5-87.1) 56.2 (43.2-73.1) 32.8 (21.4-50.3)
50-79 % 26 80.8 (67.0-97.4) 72.6 (60.5-87.1) 56.2 (43.2-73.1) 32.8 (21.4-50.3)
80-95 % 24 87.5 (75.2-100) 87.5 (75.2-100) 66.7 (50.2-88.5) 37.5 (22.4-62.9)
96-100 % 6 83.3 (58.3-100) 83.3 (58.3-100) 66.7 (37.9-100) 50.0 (22.5-100)
Unknown 1
Lepidic type
Mucinous 16 75.0 (56.5-99.5) 62.5 (42.8-91.4) 31.2 (15.1-64.6) 12.5 (3.4-45.7)
Non-mucinous 71 88.7 (81.7-96.4) 81.7 (73.2-91.2) 69.0 (59.1-80.7) 43.7 (33.5-56.9)
Mucinous and non-mucinous 14 71.4 (51.3-99.5) 63.5 (42.4-95.1) 31.8 (14.2-70.8) 7.9 (1.2-51.9)
Yr. - Year, CI - Confidence interval
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83 % 5-year survival compared to 29 %, with IB disease
and a ‘BAC’ component ≤ 50 % [18]. Higashiyama et al.
showed patients with < 50 % ‘BAC’ component in their
study had a poorer prognosis than those with > 50 %
[15]. Yokose et al. demonstrated tumors of 3 cm. or less
with > 75 % lepidic growth and a central focus of fibrosis
5 millimeters or less in maximum diameter had a 100 %
seven year survival [16]. These early invasive tumors are































































Fig. 3 Survival according to proportion of lepidic component (a) and type (b)
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smaller than this series. Okubo et al. conversely found a
worse prognosis in cases with 100 % ‘BAC’, than tumors
with a mixture of ‘BAC’ and AC [17]. This study in-
cluded a range of operations from wedge resections to
pneumonectomies. Twenty-two per cent of their cases
were mucinous, which would have influenced prognosis.
One-hundred and thirteen of 119 of these cases had
aerogenous growth. A pure ‘BAC’ pattern was seen in
only 17 patients. All the studies pre-date the latest
guidelines and it is probable that ‘BAC’ has been over-
diagnosed pathologically
Ebbert and colleagues did not quantify the percentage
of the BAC component and reported 1- and 5-year sur-
vival for 78 pure ‘BAC’ patients were 95 % and 84 % re-
spectively, and for the 178 “non-pure” patients, 93 %
and 46 %, respectively [19]. Restaging for pure ‘BAC’
cases resulted in 9/78 cases (12 %) changing stage. Com-
pared to the old staging, patients with advanced stage
under the new staging procedure had a worse 5-year
survival, (53 % vs. 45 %) but no change was observed for
stage IA. Of the 338 patients, initially diagnosed as
‘BAC’, 117 were reclassified by an experienced pulmon-
ary pathologist as “pure” and 221 were ‘non-pure’ BAC
[20]. As in our series, tumors diagnosed as BAC on the
basis of cytology or needle biopsy specimens were
excluded, but still as many as 44 patients (43 %) had less
than 50 % lepidic component and several of these would
not meet the new classification criteria for AIS. Many
Western cases reported from large centers as ‘BAC’ has
formerly been re-diagnosed as invasive AC [21].
The reproducibility in pathologist’s diagnosis of the
different histologic patterns of pulmonary AC should
also be considered. In a recent study the reproducibility
was high (k = 0.77) when 26 pathologists studied the pri-
mary patterns of this tumor [21]. Thus while this study
should be repeated for verification, a strength with the
current study is that only one histopathologist assessed
every case.
Comparisons with older series are difficult since they
were often diagnosed using old terminology, as mixed
series of ‘BAC; and AC, in addition, mucinous and non-
mucinous subtypes were not analyzed separately.
Although this series is population-based and repre-
sented all resected cases in the country reported with a
diagnosis of ‘BAC’, there is a possible selection bias in-
herent in the study in that resected cases with a lepedic
component without being classified as BAC would not
be eligible for the inclusion criteria. We do not know
the magnitude but according to the histogram in Fig. 2
the distribution indicates the study population is repre-
sentative for assessing degree of lepidic component.
Small tumors, 3 cm or less in diameter with a predom-
inant lepidic component must be sampled in their entir-
ety to exclude either AIS or AIS having foci of invasion
(minimally invasive AC). This is another limitation of
the present study, as the entire tumor and surrounding
lung tissue do not appear to have been sampled.
Conclusion
This study shows that in pulmonary AC the specific per-
centage of the lepidic component seems to be an inde-
pendent, significant prognostic factor.
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Sublobar resection 3 1.00
Lobectomy 78 0.81
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Tumor size (continuous) 100 0.99 0.88
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Mucinous and non-mucinous 13 0.99
HR – Hazard ratio
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